Lupin Limited Gains FDA Approval for New Glycerol Medication, Enhancing Urea Cycle Disorder Treatments

Lupin Limited Receives FDA Approval for Glycerol Phenylbutyrate Oral Liquid

In a significant development in the pharmaceutical landscape, Lupin Limited, a global leader in healthcare and pharmaceuticals, has officially received approval from the U.S. Food and Drug Administration (FDA) for its Glycerol Phenylbutyrate Oral Liquid, boasting a concentration of 1.1 grams per mL. This approval, announced on May 5, 2026, marks a pivotal step in providing effective treatment options for patients with urea cycle disorders (UCDs).

About Glycerol Phenylbutyrate Oral Liquid

Glycerol Phenylbutyrate Oral Liquid is designed to be bioequivalent to the reference listed drug (RLD), Ravicti® Oral Liquid, which is manufactured by Horizon Therapeutics U.S. Holding LLC. This medication serves as a critical intervention for individuals suffering from chronic UCDs that cannot be effectively managed through dietary modifications or amino acid supplementation alone. UCDs are rare genetic disorders that prevent the body from properly removing ammonia, which can accumulate and cause serious health complications.

The significant market potential for this product is evidenced by the sales figures for its RLD, which reached approximately USD 337 million for the year ending December 2025, according to IQVIA data. The introduction of Lupin's Glycerol Phenylbutyrate is expected to bolster treatment options and improve patient health outcomes significantly, addressing a critical gap in therapy accessibility.

Lupin's Commitment to Healthcare

Lupin Limited is headquartered in Mumbai, India, and has established itself as a formidable player in the global pharmaceutical industry, with products available in over 100 countries. The company operates a comprehensive portfolio that includes branded and generic formulations, complex generics, and active pharmaceutical ingredients. Its commitment to healthcare is reflected in its specialized approach covering a broad range of therapy areas, from respiratory and cardiovascular medicines to anti-infectives and women’s health products.

The company's extensive infrastructure includes 15 high-tech manufacturing facilities and 7 research centers globally, staffed by over 24,000 dedicated professionals. Lupin’s ongoing initiatives are focused on improving health outcomes through innovative solutions such as Lupin Diagnostics and Lupin Digital Health, aimed at integrating technology with healthcare delivery.

With its recent FDA approval, Lupin is poised to make a significant impact in the treatment of UCDs, demonstrating its commitment to addressing critical healthcare challenges and enhancing the quality of life for patients. As the company continues to innovate and expand its product offerings, stakeholders and healthcare providers alike are encouraged to learn more about Lupin’s journey and dedication to patient care.

Conclusion

With Lupin's FDA approval of Glycerol Phenylbutyrate Oral Liquid, there is renewed hope for patients experiencing the complexities of urea cycle disorders. This step not only enhances Lupin’s pharmaceutical footprint in the U.S. but also showcases the company’s commitment to bringing effective and accessible treatments to those in need. For further updates and information about Lupin’s diverse product range, visit their official website or follow the company on LinkedIn.